ADC Therapeutics SA Quarterly Nonoperating Income (Expense) in USD from Q2 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
ADC Therapeutics SA quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2022 to Q3 2024.
  • ADC Therapeutics SA Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$8.06M, a 12.9% increase year-over-year.
  • ADC Therapeutics SA Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$26.8M.
  • ADC Therapeutics SA annual Nonoperating Income (Expense) for 2023 was -$29.4M, a 25.4% decline from 2022.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$26.8M -$8.06M +$1.2M +12.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$28M -$6.67M +$6.33M +48.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$34.3M -$12.1M -$4.86M -66.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$29.4M $107K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$9.25M +$27.9M +75.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$13M -$25.9M -201% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$7.28M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q3 2022 -$37.1M Jul 1, 2022 Sep 30, 2022 6-K 2023-11-07
Q2 2022 $12.9M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.